Tags : Patent Dispute

Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant

Shots: Samsung Bioepis and Genentech has filed a joint stipulation of dismissal of their BPCIA patent litigation for Ontruzant, a biosimilar of Herceptin Under the settlement and license agreement, the companies jointly moved to voluntarily dismiss Bioepis’ appeal of the PTAB’s decisions upholding the patentability of U.S. Patent nos. 6,627,196 & 7,371,379, directed to cancer […]Read More